Revolutionizing dry eye care with shorter-duration cryopreserved amniotic membrane therapy

In this illuminating interview, Damon Dierker, OD, FAAO, discusses the groundbreaking potential of sutureless cryopreserved amniotic membrane therapy for moderate to severe dry eye.

Dierker, a prominent expert in the field, highlights findings from the DREAM study, showcasing the remarkable durability and efficacy of a single placement for up to three months. Notably, he reveals compelling data indicating that a shorter treatment duration of just 2 days can yield equivalent benefits, reshaping clinical recommendations and enhancing patient convenience.

As the conversation unfolds, Dierker foresees a transformative impact in 2024, with regenerative therapy playing a crucial role in addressing conditions like Neurotrophic Keratitis and persistent corneal staining.